Project/Area Number |
22591323
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Single-year Grants |
Section | 一般 |
Research Field |
Radiation science
|
Research Institution | University of Fukui |
Principal Investigator |
|
Co-Investigator(Kenkyū-buntansha) |
OOYAMA Nobuyuki 福井大学, 医学部附属病院, 講師 (20223977)
MORI Tetsuya 福井大学, 高エネルギー医学研究センター, 助教 (40397287)
KIYONO Yasushi 福井大学, 高エネルギー医学研究センター, 教授 (50305603)
TAKAHARA Noriko 福井大学, 医学部附属病院, 医員 (50572426)
YOKOYAMA Osamu 福井大学, 医学部, 教授 (90242552)
|
Project Period (FY) |
2010 – 2012
|
Project Status |
Completed (Fiscal Year 2012)
|
Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2012: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2011: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2010: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
Keywords | 核医学(PET を含む) / 前立腺癌 / エストロゲン受容体 / FES / PET / エストロゲン / FES |
Research Abstract |
The expression and role of estrogen receptor (ER) in prostate cancer receiving androgen ablation therapy remains unclear. We assessed the expression of ER by using 16α-[18F]fluoro-17β-estradiol (FES) in prostate cancer following androgen ablation therapy in vitro and in vivo. The results of the studies indicate that ERαexpression increased under androgen ablation in vitro and in vivo, showing the role of ERα in the acquaintance of androgen independency of prostate cancer. FES is a promising tracer in monitoring the expression of ERα in prostate cancer following androgen ablation therapy.
|